---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-076857"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2026-06-23T21:02:45+00:00"
generated_at: "2026-06-23T21:04:26.409145+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Theravance Biopharma SVP Áine Miller to depart Nov 15, 2026 as part of restructuring

## Summary
- Dr. Miller, SVP Development and Head of Ireland Office, will terminate on Nov 15, 2026.
- Termination is part of the restructuring announced by the Company in March 2026.
- Company will make a special pension contribution of $250,000 within 30 days of termination.
- Dr. Miller received a grant of 18,750 RSUs for continued service through the Termination Date.
- Compromise agreement and side letter entered into on June 19, 2026.

## SEC filing metadata
- accession: 0001104659-26-076857
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2026-06-23T21:02:45+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465926076857/0001104659-26-076857-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465926076857/tm2618538d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-076857
- JSON: https://secwatch.observer/filing/0001104659-26-076857.json
- Plain text: https://secwatch.observer/filing/0001104659-26-076857.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.